Sana Biotechnology Inc (SANA)
8.26
-0.04
(-0.48%)
USD |
NASDAQ |
May 22, 16:00
8.285
+0.02
(+0.30%)
After-Hours: 20:00
Sana Biotechnology Cash from Financing (TTM): 217.81M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 217.81M |
December 31, 2023 | 31.65M |
September 30, 2023 | 30.99M |
June 30, 2023 | 32.42M |
March 31, 2023 | 4.497M |
December 31, 2022 | 4.913M |
September 30, 2022 | 6.971M |
Date | Value |
---|---|
June 30, 2022 | 6.946M |
March 31, 2022 | 5.70M |
December 31, 2021 | 631.75M |
September 30, 2021 | 628.74M |
June 30, 2021 | 627.14M |
March 31, 2021 | 1.062B |
December 31, 2020 | 435.69M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
4.497M
Minimum
Mar 2023
1.062B
Maximum
Mar 2021
266.26M
Average
32.03M
Median
Cash from Financing (TTM) Benchmarks
Rocket Pharmaceuticals Inc | 191.24M |
Solid Biosciences Inc | 110.36M |
Dyne Therapeutics Inc | 433.90M |
Taysha Gene Therapies Inc | 136.74M |
Tenaya Therapeutics Inc | 51.32M |